Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

What are you doing here? Closing the gap with compelling healthcare communication

By Rachel Harris

Expanding Opportunities for Healthcare with “Digital Twins”

Brad Womble, Senior Director of Strategy, Marketing and Mergers & Acquisitions, at Jabil Healthcare dives into several thought-provoking topics, including how insights from “digital twins” can be used to improve...

Impetus Digital

regeneron headquarters

Regeneron to acquire Decibel Therapeutics in deal worth up to $213m

The transaction expands the company’s gene therapy and hearing loss pipeline

- PMLiVE

Novo Nordisk to acquire metabolic disorders specialist Inversago Pharma for $1bn

The deal includes a CB1 blocker being developed to treat metabolic syndrome and its associated complications

- PMLiVE

Gilead and Arcus drop A2R inhibitor in prostate cancer following early data analysis

The candidate is also being evaluated in second- and third-line metastatic colorectal cancer

- PMLiVE

BMS launches campaign to highlight impact of psoriasis on patient well-being

An estimated 7.5 million people in the US are affected by some form of the condition

- PMLiVE

JCVI announces advice for autumn COVID-19 booster vaccine eligibility

The Committee has advised offering the booster to those at high risk of serious disease

- PMLiVE

The importance of medical affairs

By Emily Wigginton

- PMLiVE

Innovative Trials partner with Great Ormond Street Hospital Children’s Charity

The patient recruitment company has chosen their UK charity partner for 2022/2023

Innovative Trials

- PMLiVE

BioNTech and Duality Biologics add third ADC candidate to oncology partnership

The companies announced the original agreement covering two antibody-drug conjugates in April

- PMLiVE

Novartis shares promising phase 3 results for BTK inhibitor in chronic hives

Around 60% of chronic spontaneous urticaria patients are uncontrolled by H1-antihistamines

EU flag

EMA endorses digital measure as primary endpoint in Duchenne muscular dystrophy trials

The decision qualifies SV95C as an alternative to the widely used six-minute walking test

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links